- The promise is already there for patients, but shareholders will gain as well, in our view.
- Revenues will grow 25-30% this year and margins are improving and the company has plenty of cash, it’s even looking for acquisitions.
- The shares have sold off with the general market, buying a few on a downturn will pay off longer-term.
- Their basic technology is likely to have wider applicability although developing these is a slow process.
Vericel Corporation Holds Longer-Term Promise
October 30th, 2018 · No Comments